Oppenheimer Remains Bullish on Geron Corp (GERN) Following Two Articles in NEJM
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Pre-Open Stock Movers 08/03: (PSEM) (MM) (GERN) (LCI) Higher; (FIVE) (KERX) (JOY) Lower (more...)
September 3, 2015 9:29 AM EDTPericom Semiconductor (NASDAQ: PSEM) 39% HIGHER; Diodes (NASDAQ: DIOD) and Pericom Semiconductor Corporation (NASDAQ: PSEM) announced that Diodes Incorporated and Pericom have entered into an Agreement and Plan of Merger that provides for the acquisition of Pericom by Diodes. At the effective date of the merger, each share of Pericom will be converted into the right to receive $17.00 in cash, without interest.
After-Hours Stock Movers 09/02: (GERN) (LCI) (SEAC) Higher; (FIVE) (PLNT) (VRNT) Lower (more...)
September 2, 2015 6:05 PM EDTGeron Corp (NASDAQ: GERN) 18.7% HIGHER; announced the publication of two papers in The New England Journal of Medicine (NEJM) in which the companys telomerase inhibitor, imetelstat, was shown to have disease-modifying activity thought to be associated with selective inhibition of the malignant progenitor cell clones responsible for the underlying disease in two hematologic myeloid... More
Geron Corp (GERN) Announces Publication of Two Papers in NEJM Highlighting Imetelstat
September 2, 2015 5:04 PM EDTGeron Corp (Nasdaq: GERN) announced the publication of two papers in The New England Journal of Medicine (NEJM) in which the companys telomerase inhibitor, imetelstat, was shown to have disease-modifying activity thought to be associated with selective inhibition of the malignant progenitor cell clones responsible for the underlying disease in two hematologic myeloid malignancies, essential thrombocythemia (ET) and myelofibrosis (MF). The papers are available online in the September 3rd issue at www.NEJM.org.
The data in the ET and MF study publications in The New England Journal of Medicine provide compelling... More
